BR9808758A - Derivados de cisteìna, processo para sua produção e farmacêuticos contendo os mesmos - Google Patents

Derivados de cisteìna, processo para sua produção e farmacêuticos contendo os mesmos

Info

Publication number
BR9808758A
BR9808758A BR9808758-4A BR9808758A BR9808758A BR 9808758 A BR9808758 A BR 9808758A BR 9808758 A BR9808758 A BR 9808758A BR 9808758 A BR9808758 A BR 9808758A
Authority
BR
Brazil
Prior art keywords
aromatic
optionally substituted
alkyl group
cysteine
production
Prior art date
Application number
BR9808758-4A
Other languages
English (en)
Inventor
Juliane Constanze Desi Mueller
Erich Graf Von Roedern
Louis Moroder
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of BR9808758A publication Critical patent/BR9808758A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Patente de invenção: <B>"DERIVADOS DE CISTEìNA, PROCESSO PARA SUA PRODUçãO E FARMACêUTICOS CONTENDO OS MESMOS"<D>. Composto representado pela fórmula geral (I), que se liga e inibe metaloproteinases de matriz (MMPs), onde a porção de cisteína contém um grupo tiol não-protegido, a porção de cisteína está na configuração L- ou D-, onde A significa -CO-, -SO~ 2~-, -NH-CO- ou -O-CO-, R~ 1~ significa hidrogênio, um grupo alquila saturado ou insaturado linear ou ramificado de 1 a 15 átomos de carbono ou um grupo C~ 1~-C~ 15~ alquila substituída por halogênio, mercapto, hidróxi, alcóxi, amino ou nitro ou por sistemas de anel aromático ou não-aromático carbocíclico que são opcionalmente substituídos uma ou várias vezes ou heterociclos aromáticos ou não-aromáticos, opcionalmente substituídos, seus sais farmacologicamente aceitáveis ou formas oticamente ativas dos mesmos, R significa hidróxi, grupo alquila linear ou ramificado, saturado ou insaturado de 1 a 15 átomos de carbono ou um grupo C~ 1~-C~ 15~ alquila substituído por sistemas de anel carbocíclico aromático ou não-aromatico, que são opcionalmente substituídos uma ou várias vezes ou heterociclos aromáticos ou não-aromáticos, opcionalmente substituídos, seus sais farmacologicamente aceitáveis ou formas oticamente ativas dos mesmos.
BR9808758-4A 1997-05-07 1998-05-06 Derivados de cisteìna, processo para sua produção e farmacêuticos contendo os mesmos BR9808758A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97107495 1997-05-07
PCT/EP1998/002654 WO1998050351A1 (en) 1997-05-07 1998-05-06 New cysteine derivatives, processes for their production, and pharmaceuticals containing them

Publications (1)

Publication Number Publication Date
BR9808758A true BR9808758A (pt) 2000-10-03

Family

ID=8226770

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808758-4A BR9808758A (pt) 1997-05-07 1998-05-06 Derivados de cisteìna, processo para sua produção e farmacêuticos contendo os mesmos

Country Status (10)

Country Link
EP (1) EP1034163A1 (pt)
JP (1) JP2001525800A (pt)
KR (1) KR20010012321A (pt)
CN (1) CN1261878A (pt)
AU (1) AU7652998A (pt)
BR (1) BR9808758A (pt)
CA (1) CA2289094A1 (pt)
TR (1) TR199903120T2 (pt)
WO (1) WO1998050351A1 (pt)
ZA (1) ZA983792B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021925A1 (fr) 1998-10-09 2000-04-20 Ajinomoto Co., Inc. Derives de la cysteine
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
JP4577513B2 (ja) * 2003-04-08 2010-11-10 三菱瓦斯化学株式会社 ２−アルキルシステインアミド又はその塩、並びに、それらの製造方法及び用途
JP5339708B2 (ja) * 2006-10-13 2013-11-13 サンスター株式会社 システイン類を有効成分とするマトリックスメタロプロテアーゼ−８阻害剤及び糖尿病患者又は耐糖能障害を有する者用の歯周病予防又は治療組成物
SG184988A1 (en) 2010-04-27 2012-11-29 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
KR20140100947A (ko) 2011-11-03 2014-08-18 질랜드 파마 에이/에스 Ｇｌｐ-1 수용체 효능제 펩타이드 가스트린 접합체들
CA2878991C (en) 2012-07-23 2021-12-07 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
US9896495B2 (en) 2013-10-17 2018-02-20 Zealand Pharma A/S Acylated glucagon analogues
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
JP6682432B2 (ja) 2013-11-06 2020-04-15 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
WO2016066744A2 (en) 2014-10-29 2016-05-06 Zealand Pharma A/S Gip agonist compounds and methods
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
USRE49579E1 (en) 2015-06-08 2023-07-18 University Public Corporation Osaka Non-peptidic GAPDH aggregation inhibitor
MX2019006486A (es) 2016-12-09 2019-08-01 Zealand Pharma As Agonistas duales acilados de glp-1/glp-2.
WO2023201067A2 (en) * 2022-04-14 2023-10-19 W. L. Gore & Associates, Inc. Chemical entities

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252866A (en) * 1965-06-28 1966-05-24 Mead Johnson & Co 2-hydrocarbon substituted-amido mercaptopropionamides in hair waving compositions and processes
JPH0662529B2 (ja) * 1984-07-13 1994-08-17 三共株式会社 アミノ酸誘導体
GB8709547D0 (en) * 1987-04-22 1987-05-28 Lilly Industries Ltd Organic compounds
AU4267293A (en) * 1992-05-01 1993-11-29 British Biotech Pharmaceuticals Limited Use of MMP inhibitors
MX9605333A (es) * 1994-05-04 1997-12-31 Novartis Ag Amidas de aminoacido de n-sulfonilo y n-sulfinilo como microbicidas.

Also Published As

Publication number Publication date
CA2289094A1 (en) 1998-11-12
CN1261878A (zh) 2000-08-02
JP2001525800A (ja) 2001-12-11
ZA983792B (en) 1999-11-08
KR20010012321A (ko) 2001-02-15
AU7652998A (en) 1998-11-27
EP1034163A1 (en) 2000-09-13
WO1998050351A1 (en) 1998-11-12
TR199903120T2 (xx) 2000-05-22

Similar Documents

Publication Publication Date Title
BR9808758A (pt) Derivados de cisteìna, processo para sua produção e farmacêuticos contendo os mesmos
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
BR9913255A (pt) Composto, composição farmacêutica, processo de tratamento de uma condição de doença mediada por metaloproteinase, processo para preparar um composto, e, uso de um composto
BR0314113A (pt) Derivados de amino propanol
DK0606046T3 (da) Arylsulfonamido-substituerede hydroxamsyrederivater
ES2147230T3 (es) Derivados de aminoacidos, medicamentos que contienen a estos compuestos y procedimiento para su preparacion.
BR9714787A (pt) Compostos de 4- fenilpiperidina e processo para sua preparação
BRPI0212894B8 (pt) composto ou sal do mesmo farmaceuticamente aceitável e composição farmacêutica
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
BR9812564A (pt) Amidas de ácido acilsulfamoilbenzóico, agentes protetores de plantas úteis contendo as mesmas e processos para a sua preparação
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
BR9915013A (pt) Composto, uso dos mesmos, processo para preparar os mesmos, droga, e, método para detecção in vitro para inibidores parp
ES2093947T3 (es) Compuestos hidrosolubles derivados de un homopolimero o copolimero del anhidrido maleico y aplicaciones de dichos compuestos para el soporte de moleculas biologicas.
BR9803300A (pt) Formulação farmacêutica.
BR0011738A (pt) Derivados de benzeno, processo para a preparação dos mesmos e composições farmacêuticas que os contêm
BR0314379A (pt) Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
BR9812649A (pt) Compostos contendo anéis de seis membros, processo para sua preparação, e seu uso como medicamentos
AR018139A1 (es) Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento.
BR0207408A (pt) Azóis como inibidores de malonil-coa decarboxilase úteis como moduladores metabólicos
BR9916004A (pt) Inibidores de proteinase c de pró-colágeno
BR0304203A (pt) Processo para a sìntese industrial de tetraésteres de ácido 5-[bis (carboximetil)amino]-3-carboximetil-4-ciano-2-tiofen ocarboxìlico e aplicação à sintese de sais bivalentes de ácido ranélico e seus hidratos
MX9307232A (es) Arilcicloalquilaminas n,n-disustituidas, sus sales, medicamentos que contiene estos compuestos y su empleo, asi como procedimientos para su preparacion.
BR0008297A (pt) Uso de 4,6-o-(benzilideno-d1) -d-glucopiranose, 4,6-o-benzilideno-l-glucopiranose, e/ou 4,6-o-(benzilideno-d1) -l-glucopiranose, ou um sal farmacêutico aceitável dos mesmos, derivado de benzaldeìdo composição farmacêutica, e, processo para a fabricação da mesma
BRPI0411308A (pt) composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto

Legal Events

Date Code Title Description
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1891 DE 03/04/2007.